DelveInsight's "VERZENIO Market Size, Forecast, and Market Insight Report" highlights the details around VERZENIO, which is a targeted treatment known as ...

The researchers also investigated the PIK3CA/AKT1/PTEN pathway, which is known to be a major signalling pathway in multiple types of cancer. It has roles in controlling the survival and spread of ...

Our pipeline includes two Phase 1 therapies in development for solid tumors: ALTA2618, a first-in-class, oral mutation-selective inhibitor for AKT1 E17K-driven cancers, and ALTA3263, a potential ...

As VERZENIO gains traction in early-stage treatments and broadens its approved uses, its revenue is expected to keep growing. While the global CDK4/6 inhibitor market remains highly competitive ...

LAE002 (afuresertib) is a potent AKT inhibitor that inhibits all three AKT isoforms (AKT1, AKT2 and AKT3) as well as one of the only two AKT inhibitors in late-stage development for breast and ...

HER2-negative advanced breast cancer – regardless of their PIK3CA/AKT1/PTEN mutational status – and is now in phase 3 testing; 3) Daprodustat: GSK is vying to become the first drug in the HIF ...

This drug blocks some types of the AKT protein. It can be used if the cancer cells have changes in any of the AKT1, PIK3CA, or PTEN genes. Everolimus (Afinitor). This drug blocks a protein ...

Terremoto Biosciences patents AKT1 inhibitors for cancer Feb. 26, 2025 Terremoto Biosciences Inc. has synthesized new 3 H -imidazo[4,5- b ]pyridine compounds acting as RAC-α serine/threonine-protein ...

Disruptions to genes linked to brain health and development — such as DISC1, NRG 1, and Akt1 — may play a role, too. Research also suggests that some antipsychotic medications used to treat ...

Result: A total of 538 targets of GSP and 10795 DU-related targets were predicted; Venn analysis identified 215 potential targets for GSP to accelerate DU wound healing; PPI network analysis suggested ...

NEW YORK – Alterome Therapeutics said on Monday it has started treating patients with KRAS-mutant advanced solid tumors with its KRAS inhibitor ALTA3263 in a Phase I trial.